Guneet Walia, PhD, on Central Issues in Lung Cancer Care
2015 IASLC World Conference on Lung Cancer
Guneet Walia, PhD, of the Lung Cancer Foundation, summarizes some key presentations: bridging the quality chasm, patients’ attitudes and physicians’ perceptions on maintenance therapy, and patient advocacy.
Pasi A. Jänne, MD, PhD
Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, summarizes a workshop he conducted on the state of the art in next-generation sequencing of lung cancer (Abstract WS 01.07).
William D. Travis, MD
William D. Travis, MD, of Memorial Sloan Kettering Cancer Center, gives an update on the WHO classification, which is crucial for optimal personalized treatment of lung cancer patients (Abstract PLEN02.01).
Christine D. Berg, MD
Christine D. Berg, MD, of Johns Hopkins Medicine, discusses how increased insurance coverage should dramatically increase lung cancer screening. If done correctly—which will be a challenge—screening will help improve the prognosis of patients with lung cancer (Abstract PLEN 01.01).
Naiyer A. Rizvi, MD
Naiyer A. Rizvi, MD, of Columbia University, offers an update on immune checkpoint inhibitors in non–small cell lung cancer: what’s new and what’s next.
Philip Bonomi, MD
Philip Bonomi, MD, of Rush Medical College, summarizes the findings on anamorelin and its use in advanced NSCLC for improvement in anorexia/cachexia symptoms (Abstracts ORAL 29.01, ORAL 29.02).